Effects of aspirin combined with low molecular weight heparin in the treatment of severe pre-eclampsia

Objective To investigate the effects of aspirin combined with low molecular weight heparin in the treatment of patients with severe pre-eclampsia. Methods Seventy-two patients with severe pre-eclampsia admitted to Weihai Maternal and Child Health Hospital from March 2016 to March 2018 were selected. According to random number table method, they were divided into control group and observation group, with 36 cases in each group. On the basis of routine treatment, the control group was treated with aspirin, while the observation group was treated with aspirin combined with low molecular weight heparin. The levels of coagulation factors, pregnancy outcomes and adverse reactions were compared between the two groups. Results After treatment, the levels of fibrinogen (FIB) and D-dimer (DD) in the observation group were (3.29±0.27) g/L and (1.85±0.68) mg/L respctively, lower than the (4.56±0.43) g/L and (2.91±0.53) mg/L in the control group (P 0.05). The incidence of adverse reactions in the observation group was 16.67% (6/36), higher than the 11.11% (4/36) in the control group, but the difference was not statistically significant (P>0.05). Conclusions Aspirin combined with low molecular weight heparin can effectively improve the level of coagulation factor in patients with severe preeclampsia, optimize the pregnancy outcome, without significant increase in incidence of adverse reactions, of which the safety is relatively high. Key words: Aspirin; Severe pre-eclampsia; Low molecular weight heparin; Coagulation factor; Pregnancy outcome; Adverse reactions